Switzerland Dr Nicolas Fischer introduces Light Chain Bioscience, a Swiss biotech company focusing on the discovery and development of bispecific antibodies using proprietary technology. Fischer also outlines the competitiveness of Light Chain’s platform, the company’s partnership strategy, and his goals for future growth. There is no question that bispecific and…
Switzerland Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019, leaving behind a storied career in oncology R&D at Novartis and Gilead. In an exclusive interview, Riva outlines his motivations behind taking on this new challenge, how the company’s approach to oncology treatment differs from – and…
Germany After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into public opinion on healthcare STADA, based in Bad Vilbel, focuses on a two-pillar strategy consisting of generics, including specialty…
Europe Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit, with the UK diverging from the rest of the continent in regulatory terms and the launch of the European Commission’s Pharmaceutical Strategy for Europe. After four…
Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…
Switzerland Regarded as one of the world’s leading regulatory bodies, Swissmedic stands alongside its equivalents in Europe, Japan, Canada, and Australia in terms of the evaluation and approval of new drugs. Although its approval times are increasing, raising doubts about Swissmedic’s continued place at the top table of global regulators, initiatives…
Europe With Rare Disease Day falling on 28 February, PharmaBoardroom dedicates this month to exploring the global rare disease landscape, highlighting key trends and developments as well as profiling the most innovative global players in this space. We start the party off with five of the most promising clinical-stage biotech companies…
Switzerland Dr Chris Martin, CEO and co-founder of Swiss-headquartered antibody-drug conjugate cancer company, ADC Therapeutics, shares the company’s journey over the past decade, the exciting progress of their two lead candidates, the process of building their commercial organization in the US, and his perspectives on Big Pharma partnerships. We have…
Europe The journey of EUnetHTA began back in 2004, when the European Commission and Council of Minsters requested the establishment of a sustainable European network on Health Technology Assessment (HTA) as “a political priority”, work on which was properly initiated in 2005 when a group of 35 organizations came together to…
Switzerland In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical breakthroughs, and why scientific innovation continues to motivate him. When you have started two companies, people think that you…
Europe While 2020 may have seemed like the year the world stood still for many, the pharma industry went into overdrive, working around the clock to ensure security of supply as well as develop diagnostics, treatments, and vaccines for COVID-19. Recruitment also continued apace; here four recent country manager appointees share…
France The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its in-house product and the impact of this on the country’s global scientific standing. Also featured are the rising problem of anti-vaccine sentiment, an exclusive…
See our Cookie Privacy Policy Here